Predictors of Respiratory Failure in SARS-Cov-2 Infection
Predictors of Respiratory Failure Requiring ICU Admission Among Hospitalized Patients With SARS-Cov-2 Infection
The emergence of SARS-CoV-2 is currently engaging and consuming most of resources of efficient healthcare systems in Europe, and several hospitals are currently experiencing a shortage of ICU beds for critically-ill patients with SARS-CoV-2 pneumonia.
A risk stratification based on clinical, radiological and laboratory parameters seems necessary in order to better identify those patients who may need ICU admission and/or those who may benefit from a prompt antiviral therapy
研究概览
地位
详细说明
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
Bologna、意大利、40138
- 招聘中
- University of Bologna - Department of Medical and Surgical Sciences
-
接触:
- Pierluigi Viale, MD
- 电话号码:+ 39 051 214 3018
- 邮箱:pierluigi.viale@unibo.it
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Hospitalized patients with microbiologically confirmed diagnosis of SARS-CoV-2 infection
- Age > 17 years
Exclusion Criteria:
- Invasive mechanical ventilation within 12 hours from hospital admission
学习计划
研究是如何设计的?
设计细节
- 观测模型:队列
- 时间观点:追溯
队列和干预
团体/队列 |
---|
Derivation cohort
Derivation cohort: Italian retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from February 20 to March 19 2020. . |
Validation cohort
Validation cohort: European and non-European retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from March 19 to April 18 2020.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Respiratory failure
大体时间:14 days
|
Composite of ICU admission or SpO2<92% with 100% FiO2 of oxygen treatment (reservoir mask or CPAP or NIV), respiratory rate >30 bpm, respiratory distress
|
14 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Occurence of bacterial superinfection
大体时间:14 days
|
Incidence of bacterial superinfection among ventilated patients with SARS-CoV-2 pneumonia
|
14 days
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- PREDI-CO
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
SARS-CoV-2 肺炎的临床试验
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and Prevention尚未招聘
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical Co...尚未招聘
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College主动,不招人
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and Prevention完全的
-
Peking UniversityCenters for Disease Control and Prevention, China; Beijing Pinggu District Hospital; Peking University...完全的
-
University Hospital, Montpelliersociete SkillCell - 97198 Jarry; CNRS Alcediag UMR9005 - societe Sys2Diag - 34184 Montpellier完全的